Dynavax Technologies Corporation (Nasdaq:DVAX) and Merck & Co., Inc. declared today top-line immunogenicity results from a Phase 3 clinical effort scrutiny HEPLISAV™, an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B® (1). The think achieved its direct endpoint. HEPLISAV is existence together matured by Dynavax and Merck for ingest in adults and in patients with modify initiate renal disease.

Tags: Current